gilead sciences news - Search News

Gilead, Leo Pharma

Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to $1.7B to jointly develop and commercialize LEO’s anti-inflammatory drugs. As part of the deal,

FierceBiotech · 1d

Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal wit | Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now,

Reuters · 1d

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

Business Insider · 1d

Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule

Business Wire · 1d

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO

Bloomberg L.P. · 1d

Gilead, Leo Pharma Form Pact Focused on Inflammatory Diseases

Gilead Sciences and LEO Pharma said they formed a strategic partnership to focus on the potential treatment of patients with inflammatory diseases.

Gilead Sciences (NASDAQ:GILD) Upgraded at Morgan Stanley

Morgan Stanley upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note published on Friday, MarketBeat.com reports. Morgan ...

FierceBiotech4d

Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

2don MSN

Gilead upgraded by Morgan Stanley on lenacapavir potential

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," ...